Integrated Biopharma Inc (INBP) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access INBP Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Integrated Biopharma Inc's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent5.83
Cash & Short-term Investments5.00
Accounts receivable3.66
Inventories8.12
Other Current Assets0.37
Total Current Assets17.97
Equipment/Property/Plant Net1.70
Deposits Assets, Noncurrent AS0.05
Other Assets, Noncurrent6.95
Operating Lease Right Of Use Asset3.20
Total Assets26.67
Liabilities
Accounts Payable, Current AC2.97
Accrued Liabilities And Other Liabilities0.00
Other Liabilities, Current2.56
Total Current Liabilities5.53
Total Long-term Debt0.00
Other liabilities, Noncurrent2.16
Operating Lease Liability Current1.14
Operating Lease Liability Noncurrent2.08
Total Liabilities7.69
Stockholders' Equity
Treasury Stock Common Value-0.10
Common Stock Value0.06
Additional Paid In Capital Common Stock51.91
Retained Earnings / Accumulated Deficit-32.90
Other Equity0.00
Common Stockholder's Equity18.98
Total Stockholder's Equity18.98
Liabilities & Stockholder's Equity26.67
4 historic quarters locked

Sign in to unlock the full Integrated Biopharma Inc balance sheet history.

About Integrated Biopharma Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-015899

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.